Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyAetna noninvasive hepatic fibrosis coverage | Open…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0690

    Noninvasive Tests for Hepatic Fibrosis

    Customize your policy alerts

    Sign up for Aetna Policy 0690 alerts

    Get alerted when Policy 0690 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, investigational determinations, and coding guidance for noninvasive tests used to detect or monitor hepatic fibrosis in members with chronic liver disease.

    Policy Summary
    PayerAetna
    PolicyNoninvasive Tests for Hepatic Fibrosis
    Policy CodePolicy 0690
    Change TypeAnnual review — no material changes
    Effective Date08/13/2004
    Last ReviewFeb 20, 2024
    Next Review Date07/25/2024
    Key ActionSubmit claims with the listed CPT codes and matching ICD-10 diagnosis codes and document the clinical indication and test result (numeric score or kPa) in the medical record.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4medically necessary tests
    ≤2/yrmax frequency
    6 momin interval after biopsy
    multipleinvestigational items
    includedCPT/ICD lists
    02/20/2024last review

    Coverage Criteria — Noninvasive Tests for Hepatic Fibrosis

    Experimental / Investigational (Not covered)

    The following are considered experimental and investigational (not covered) because effectiveness has not been established:

    ARFI: Acoustic radiation forced impulse (ARFI) for distinguishing hepatic cirrhosis from non-cirrhosis and for all other indications is investigational.
    Artificial intelligence algorithms for distinguishing healthy versus NAFLD/NASH, fibrosis versus non-fibrosis, screening/early diagnosis of fatty liver disease are investigational.

    No specific CPT code

    FibroTest-ActiTest/HCV-FibroSure for other indications: Use of FibroTest-ActiTest/HCV-FibroSure for indications other than distinguishing cirrhosis versus non-cirrhosis (eg, diagnosis/monitoring of primary biliary cholangitis) is investigational.
    Policy Summary
    PayerAetna
    PolicyNoninvasive Tests for Hepatic Fibrosis
    Policy CodePolicy 0690
    Change TypeAnnual review — no material changes
    Effective Date08/13/2004
    Last ReviewFeb 20, 2024
    Next Review Date07/25/2024
    Key ActionSubmit claims with the listed CPT codes and matching ICD-10 diagnosis codes and document the clinical indication and test result (numeric score or kPa) in the medical record.
    SourceLink
    On This Page
    Coverage Criteria — Noninvasive Tests for Hepatic FibrosisCoding — CPT and ICD-10 GuidanceProvider Actions — Documentation, Authorization, and Denial RisksBackground — Clinical Context and Evidence SummaryDefinitions — Tests, Metrics, and TermsRevision History
    Hepatic artery resistive index for evaluation of fibrosis progression in NAFLD is investigational.
    MRE for other indications: Magnetic resonance elastography for distinguishing cirrhosis from non-cirrhosis in hepatitis C or other chronic liver diseases and for other indications is investigational.
    Quantitative MR (LiverMultiScan): Quantitative magnetic resonance (eg, LiverMultiScan) for analysis of liver tissue composition is investigational.
    Serum ferritin as a biomarker for detecting or monitoring hepatic fibrosis is investigational.
    TE for specific non-covered indications: Transient elastography for detection of esophageal varices, diagnosis of acute cellular rejection after liver transplantation, diagnosis of glycogenic hepatopathy, diagnosis of portal hypertension, evaluation of alpha-1 antitrypsin deficiency, Alagille syndrome, Gilbert syndrome, and routine follow-up of liver transplant recipients is investigational.
    Listed serum marker tests: Specific serum marker tests (eg, angiotensin converting enzyme, FibroMAX, FibroSpect, HepaScore, LIVERFAST, MFAP4, various microRNAs, NASH FibroSure, plasma cytokeratin-18, SIPA1L1) are investigational for detecting or monitoring hepatic fibrosis.

    Evidence-based coverage considerations

    Summary of evidence-based conclusions from cited literature:

    Tests with relatively higher reported performance: FibroTest/FibroSure, Fibrometer, HepaScore, and FibroScan show higher diagnostic accuracy in several studies and meta-analyses, with FibroTest mean standardized AUROC ~0.84 across etiologies, but indeterminate ranges and limitations persist.

    See Halfon et al and related meta-analyses

    General coverage stance

    Role of noninvasive tests in assessing liver disease severity

    Use of noninvasive tests for staging: Noninvasive tests (serum markers, transient elastography, routine labs) are useful for staging fibrosis and determining presence or absence of cirrhosis; liver biopsy is rarely required if noninvasive parameters are concordant.see policy thresholds

    Guideline-based recommendations (AASLD/IDSA, WHO) cited

    Cirrhosis definition for HCV management

    Simplified HCV treatment pathway eligibility

    Evidence of cirrhosis: Cirrhosis may be defined by FIB-4 > 3.25 OR transient elastography stiffness > 12.5 kPa OR proprietary serologic tests exceeding proprietary cutoffs OR clinical/imaging evidence (eg, liver nodularity, splenomegaly, platelet count <150,000/mm3) OR prior liver biopsy showing cirrhosis.explicit thresholds listed

    Used to determine HCV treatment algorithm and follow-up needs

    Relative test performance

    Comparative performance considerations

    Test performance summary: APRI has lower performance than FIB-4, transient elastography (TE), and FibroTest for identifying advanced fibrosis in chronic hepatitis B and C; FibroTest and TE have similar pooled performance for cirrhosis; ELF may outperform FIB-4 in some cohorts.AUROC differences cited in source studies

    Performance varies by etiology and study methodology

    Appropriate use and evidence summary

    Covered when evidence supports diagnostic utility for advanced fibrosis/cirrhosis and testing is performed in appropriate clinical context

    General conditions for use

    • Test-specific evidence: ELF shows very high AUC for cirrhosis versus MRE (eg, AUC 0.986) with high specificity at reported cutoffs; FibroScan shows high AUC for cirrhosis (up to 0.96) but lower accuracy for milder fibrosis.

      See Sherman et al; Foucher et al; Inadomi et al

    • Contextual limitations: Transient elastography measurements are frequently elevated during acute liver injury and are unreliable for detecting pre-existing fibrosis/cirrhosis in that setting.

      See Sagir et al

    Appropriate use and limitations

    Clinical utility and appropriate use considerations summarized from evidence:

    Use TE when: Patient has chronic liver disease (eg, chronic hepatitis C, B, NAFLD) and assessment for cirrhosis or fibrosis staging is needed.

    TE has best accuracy for detecting cirrhosis; diagnostic accuracy for significant fibrosis is variable and disease-dependent

    Consider TE particularly when: Noninvasive monitoring is preferred over biopsy, or TE combined with serum markers could avoid initial biopsy in many chronic hepatitis C patients.

    Combination improves accuracy

    Do not rely on TE alone when: Patient has acute liver injury or very elevated bilirubin/ALT, obesity, ascites, or other factors influencing stiffness; in these settings TE may give false-high values and biopsy or alternative assessment may be needed.

    Acute inflammation can transiently elevate LSM; failure rates higher in obesity/ascites

    Evidence-supported indications and limitations

    Summarized clinical evidence supports TE as a useful noninvasive diagnostic tool in specific contexts but with variable thresholds and limitations.

    TE diagnostic utility: TE shows good accuracy versus biopsy for staging fibrosis and can reliably distinguish cirrhosis from non-cirrhosis; performance is influenced by obesity, ascites, steatosis, and etiology.varies by study

    Supported by systematic reviews and assessments noting limitations and need for further study

    TE in special populations: In pediatrics and transplant settings TE may aid assessment (pooled pediatric sensitivity 90%, specificity 79%, AUROC 0.92); TE has been studied for graft damage/ACR with suggested study-specific cutoffs but cannot yet replace biopsy.examples: pediatric cutoffs and ACR study cutoffs vary

    Limited by small sample sizes in some studies

    Evidence-based diagnostic and prognostic findings

    Findings summarized from cited studies and reviews

    Comparative performance and mpMRI: MRE and mpMRI indices (eg, cT1, PDFF) correlate with histology; combined mpMRI indices achieved AUCs ~0.88 for NASH in small prospective studies but require multicenter validation.mpMRI index cutoff 6 reported in study

    McDonald et al; prospective mpMRI studies

    Pediatric feasibility: Transient elastography is feasible in children >2 years with valid LSMs and correlates with portal hypertension and laboratory parameters; scans are more frequently invalid in children <2 years.

    ChiLDReN and pediatric systematic reviews

    This policy identifies which noninvasive tests for hepatic fibrosis Aetna considers medically necessary, which are experimental/investigational (not covered), and important constraints and limitations that affect appropriate use and claims documentation. The policy lists covered modalities including transient elastography (e.g., FibroScan), FibroTest‑ActiTest/HCV‑FibroSure, magnetic resonance elastography (MRE) for certain NASH indications, and the Enhanced Liver Fibrosis (ELF) test, and it also specifies multiple procedures and biomarkers considered investigational (for example, ARFI, quantitative mpMRI/LiverMultiScan, serum ferritin, and various miRNA assays).

    When tests are used clinically, claims should match the listed CPT/HCPCS and ICD‑10 coding and be supported by documentation of the clinical indication and numeric test results where applicable (for example, FibroTest score, ELF index, or median liver stiffness in kPa). The policy identifies numerous CPT and ICD‑10 codes that are not covered for investigational indications (for example, quantitative MRI CPT codes 0648T–0724T and ferritin CPT code 82728) and notes that artificial intelligence approaches currently have no specific billing code and are considered investigational for fibrosis/NAFLD applications.

    The coverage stance emphasizes that noninvasive tests have the greatest validated utility for identifying advanced fibrosis or cirrhosis rather than for distinguishing early or intermediate stages. Guideline and systematic‑review evidence cited in the policy indicate that serum marker panels and imaging techniques can reduce the need for biopsy in some patients but none fully supplants liver biopsy across all clinical scenarios. UpToDate and guideline summaries are cited to support that serum assays and imaging remain imperfect substitutes for histology.

    The policy includes explicit constraints to limit overuse and duplicate testing: performance of transient elastography, FibroTest‑ActiTest/HCV‑FibroSure, MRE, or ELF more than twice per year is considered not medically necessary, and repeating any of these noninvasive fibrosis tests within 6 months following a liver biopsy or another listed fibrosis test is considered not medically necessary and may be denied. It also notes contexts in which specific tests are unreliable or not indicated (for example, transient elastography is unreliable during episodes of acute liver injury and noninvasive tests have no role in diagnosing glycogenic hepatopathy in place of biopsy).

    The document highlights evidence limitations for emerging technologies: mpMRI/LiverMultiScan and other quantitative MRI indices have limited multicenter and cross‑vendor validation and therefore are considered investigational pending broader validation; published single‑center studies require further prospective, multi‑site validation before routine clinical replacement of biopsy. Similarly, the policy cites studies showing lack of correlation (e.g., serum ACE with fibrosis stage) or inadequate sensitivity/specificity (e.g., CK‑18 for NASH) to justify investigational determinations for several serum markers.

    Finally, the policy underscores provider documentation expectations and authorization considerations: when reporting elastography include the median kPa and number of valid measurements, document numeric serum panel scores when used for management, and submit claims with the matching diagnosis codes. The policy does not specify a uniform prior authorization requirement in the excerpt; providers are directed to the Clinical Policy Bulletin and plan provisions for any plan‑specific prior authorization rules.

    The policy excerpt contains no single blanket exclusion list phrased as universal coverage denials in these chunks, but it does enumerate numerous investigational indications and associated CPT/ICD‑10 entries for which coverage is not supported. International and guideline sources cited in the background sections (for example, AASLD/WHO/NIH reviews and systematic reviews) do not endorse routine replacement of biopsy by noninvasive tests because of variable accuracy and incomplete validation.

    Guideline context and systematic reviews summarized in the policy consistently note that noninvasive approaches may be useful as screening or to exclude advanced fibrosis, and that combining serum indices with elastography can improve diagnostic accuracy and reduce the need for biopsy in some patient groups. However, these sources also advise caution: many noninvasive tests have indeterminate zones, and external validation of stage‑specific cutoffs is often lacking, which limits universal adoption and supports selective, indication‑driven use rather than broad replacement of histologic assessment.

    The policy reinforces the evidence‑based conclusion that no serum test can fully supplant liver biopsy. UpToDate and systematic review citations emphasize that while serum marker panels and algorithms (e.g., FibroTest/FibroSure, HepaScore, APRI/FIB‑4) provide useful, noninvasive risk stratification, they have limitations including variable specificity for liver‑derived fibrosis, susceptibility to confounding by inflammation or comorbid conditions, and discordance with biopsy in a substantial minority of cases. Consequently, biopsy remains the reference standard when definitive staging or diagnostic clarity is required.

    The policy explicitly warns that transient elastography (FibroScan) should not be relied upon to diagnose pre‑existing cirrhosis during episodes of acute liver injury. Cited evidence (Sagir et al.) demonstrates that liver stiffness measurements are frequently and transiently elevated in acute hepatic injury, producing false‑positive values suggestive of cirrhosis that resolve as the acute process abates. Testing performed in this setting may therefore be misleading and can result in inappropriate clinical conclusions or interventions.

    Consistent with the above, the policy describes that transient elastography (TE) is unsuitable for detecting cirrhosis/fibrosis in patients with acute liver damage because TE frequently yields pathologically high values during acute hepatitic episodes. The background literature and technology assessments note that inflammation and elevated bilirubin can confound stiffness measurements, and recommend against relying on TE results obtained during the acute phase for chronic fibrosis staging.

    For glycogenic hepatopathy (GH), the policy states that noninvasive tests such as FibroScan or FibroTest have no role in diagnosing GH or in distinguishing GH from NAFLD; liver biopsy remains the diagnostic gold standard when the diagnosis is uncertain. Reviews and case series cited indicate that GH is clinically and biochemically similar to NAFLD and that imaging and serum tests are not pathognomonic, so biopsy or other definitive approaches may be required for diagnostic certainty in select patients.

    The evidence for multiparametric MRI approaches (for example, LiverMultiScan, cT1‑based indices) is described as promising but limited. The policy notes that single‑center studies and small cohorts report correlations between mpMRI parameters and histologic measures and that combined mpMRI indices have shown favorable diagnostic AUCs for NASH in early studies, but cross‑vendor, multi‑center validation is lacking. Consequently, mpMRI / LiverMultiScan is considered investigational pending further validation and prospective outcome data.

    Guideline context in the policy indicates that UpToDate and other reviews do not presently include mpMRI/LiverMultiScan as an established management tool for NAFLD/NASH. While mpMRI techniques are noted as technically promising for quantifying fat, iron, and fibroinflammatory change, major reviews and guideline summaries cited in the policy do not endorse mpMRI as a routine replacement for biopsy or standard management pathways, pending more extensive validation.

    The policy cites evidence that serum angiotensin‑converting enzyme (ACE) levels do not correlate with histologic fibrosis stage in chronic hepatitis C. Akar and colleagues found no statistical relationship between serum ACE and fibrosis stage in CHC cohorts, indicating that ACE is not supported as a diagnostic marker for staging hepatic fibrosis in the cited study population.

    Authors of studies and reviews summarized in the policy note that elastography cannot currently replace liver biopsy to distinguish acute cellular rejection from recurrent disease or other graft pathology after transplantation. Evidence to date is limited, cutoffs are inconsistent, and confounding vascular or biliary changes may alter elastography results. Although TE may be useful as a noninvasive adjunct in transplant follow‑up research, the policy indicates that biopsy remains required when distinguishing rejection from other graft disorders.

    The reference excerpts included in the policy do not present an enumerated list of universal coverage exclusions beyond the investigational indications and code listings already described; rather, they summarize the literature and guideline positions that inform the policy. Investigational determinations are supported by cited evidence gaps and validation limitations rather than by a single explicit exclusion clause in the background citations.

    The policy reiterates that transient elastography is unreliable for detecting cirrhosis in the setting of acute liver damage; the Sagir et al. study showed that many patients with acute liver injury had transiently elevated liver stiffness suggestive of cirrhosis despite no clinical, imaging, or histologic evidence of cirrhosis. Therefore TE results obtained during acute hepatic injury should not be used to infer chronic cirrhosis without further corroboration.

    To limit unnecessary utilization the policy defines an overfrequency constraint: performance of listed noninvasive fibrosis tests (transient elastography, FibroTest‑ActiTest/HCV‑FibroSure, magnetic resonance elastography, and ELF) in excess of 2 times per year is considered not medically necessary. Additionally, repeating these tests within 6 months after a liver biopsy or another specified fibrosis test is considered not medically necessary. These thresholds are intended to balance clinical monitoring needs with the limited evidence supporting frequent serial testing and to reduce duplicative testing.

    The policy reflects the evidence‑based conclusion that serum marker models and other noninvasive tests are currently insufficiently accurate to routinely replace liver biopsy for staging hepatic fibrosis in many patients. Systematic reviews and guideline statements cited indicate that while noninvasive tests are helpful for excluding advanced fibrosis or identifying patients who may not require immediate biopsy, their variable accuracy across etiologies, indeterminate ranges, and confounding factors limit universal replacement of histologic assessment.

    Beyond the specific overfrequency and timing limitations, the policy does not list additional discrete scenarios labeled as 'not medically necessary' in these excerpts; rather, it emphasizes investigational status or limited evidence for specific technologies and clinical contexts. The investigational list includes multiple serum tests, imaging modalities (quantitative mpMRI), and procedural indications for TE (eg, routine transplant surveillance, glycogenic hepatopathy diagnosis, esophageal varices detection) where evidence is insufficient to support routine coverage.

    The policy underscores that noninvasive tests should not be used to universally replace liver biopsy for all patients. Guideline and meta‑analytic evidence in the excerpts indicate that these tests are most reliable for detecting advanced fibrosis or cirrhosis and perform less well for early or intermediate fibrosis stages. Where definitive staging impacts management, or where noninvasive results are discordant or indeterminate, liver biopsy remains indicated.

    Sequential or combined strategies (for example, initial serum screening with FIB‑4/APRI followed by ELF or TE for indeterminate results) are discussed in the background as approaches that can increase diagnostic accuracy and may reduce but not eliminate the need for biopsy; such strategies require clinical judgment and, in some cases, further validation.

    The policy cautions that elastography techniques currently lack validated, universally accepted stiffness cutoffs for definitive noninvasive staging across all fibrosis stages. Meta‑analyses and reviews note a wide range and overlap of stiffness thresholds between stages and emphasize that no optimal stiffness cut‑offs for individual fibrosis stages have been validated in independent cohorts. Thus, TE and related elastography results should be interpreted within the clinical context and, in many cases, used in combination with serum markers or imaging rather than as standalone definitive stage assignments.

    The background and coding excerpts do not present a concise single‑sentence 'not medically necessary' statement beyond the overfrequency and duplicate testing rules; rather, the investigational determinations, limitations, and absence of sufficient evidence for particular tests and indications serve as the rationale for noncoverage of those listed procedures and codes. The policy therefore relies on evidence summaries and investigational listings to delineate noncoverage rather than on an additional blanket NMN statement within the provided excerpts.

    The policy states that mpMRI/LiverMultiScan and other quantitative multiparametric MRI techniques are not established to broadly replace liver biopsy. Early validation studies show correlation with histology for parameters such as cT1 and PDFF and reasonable diagnostic performance in select cohorts, but limitations include small, single‑center study populations, lack of independent validation cohorts, and potential cross‑vendor variability; therefore, mpMRI is currently classified investigational for general fibrosis staging pending further evidence.

    Evidence is insufficient to support imaging alone to diagnose NASH or to rely on single serum biomarkers for NASH staging. Systematic reviews and pooled analyses report that imaging modalities (including MRE) and biomarkers such as CK‑18 have limited sensitivity or heterogeneous performance for NASH; CK‑18 in particular shows modest AUROC values and limited sensitivity, making it inadequate as a lone screening or staging test. The policy therefore treats these modalities as adjunctive and requiring further validation before routine standalone diagnostic use.

    The policy repeatedly documents limitations in the evidence base and the need for further research and multicenter validation for several emerging techniques (including mpMRI indices, AI/ML models, and some serum biomarkers). Single‑center studies, small cohorts, lack of validation datasets, and technical variability (eg, scanner differences, patient iron load effects) are cited as reasons that the existing data are insufficient to support routine clinical adoption for many of these newer tests.

    The document excerpts that support the investigational listings do not themselves present explicit 'not medically necessary' (NMN) scenarios beyond the overfrequency and duplicate testing constraints. Instead, investigational determinations are based on limited or inconsistent evidence in the literature, lack of multicenter validation, and guideline positions that advise cautious or limited use pending additional data. Where the policy designates a test investigational, corresponding CPT/ICD entries are listed as not covered for those indications.

    Coding — CPT and ICD-10 Guidance

    Transient elastography (e.g., FibroScan) CPT codesCPT
    76981Ultrasound, elastography; parenchyma (eg, organ)
    91200Liver elastography, mechanically induced shear wave (eg, vibration), without imaging, with interpretation and report
    76982Ultrasound, elastography
    76983Ultrasound, elastography
    FibroTest-ActiTest / HCV-FibroSure / NASH FibroSure CPT codesCPT
    81596Infectious disease, chronic hepatitis C virus (HCV) infection, six biochemical assays ... prognostic algorithm reported as scores for fibrosis and necroinflammatory activity in liver
    0003MLiver disease, ten biochemical assays ... quantitative scores for fibrosis, steatosis and nonalcoholic steatohepatitis (NASH) [NASH FibroSURE]
    Magnetic resonance elastography CPT codesCPT
    76391Magnetic resonance (eg, vibration) elastography
    Enhanced Liver Fibrosis (ELF) CPT codeCPT
    81517Liver disease, analysis of 3 biomarkers (HA, PIIINP, TIMP-1) using immunoassays, prognostic algorithm reported as a risk score
    Quantitative magnetic resonance CPT codes (not covered)CPTNot Covered
    0648TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content) obtained without diagnostic MRI
    0649TQuantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content) obtained with diagnostic MRI
    0697TQuantitative magnetic resonance for analysis of tissue composition, obtained without diagnostic MRI; multiple organs
    0698TQuantitative magnetic resonance for analysis of tissue composition, obtained with diagnostic MRI; multiple organs
    0723TQuantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic MRI
    0724TQuantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic MRI
    Other related CPT / laboratory codesCPT
    0166ULiver disease, 10 biochemical assays ... algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation
    83520Immunoassay, analyte, quantitative; not otherwise specified
    83883Nephelometry, each analyte not elsewhere specified
    88342Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure
    82977Glutamyltransferase, gamma (GGT)
    Covered ICD-10 diagnosis codes (examples listed)ICD-10
    E83.110Hereditary hemochromatosis
    K75.81Nonalcoholic steatohepatitis (NASH)
    K76.0Fatty (change of) liver, not elsewhere classified
    K83.01Primary sclerosing cholangitis
    B18.0Chronic viral hepatitis B
    B18.1Chronic viral hepatitis B
    B18.2Chronic viral hepatitis C
    K70.0Alcoholic fatty liver
    K77Other liver disease
    Z94.4Liver transplant status
    ICD-10 and CPT codes noted as not covered for listed indicationsmixedNot Covered
    E74.00Glycogen storage disease [glycogenic hepatopathy]
    E74.09Glycogen storage disease [glycogenic hepatopathy]
    E80.4Gilbert syndrome
    E88.01Alpha-1-antitrypsin deficiency
    I85.00Esophageal varices
    I85.01Esophageal varices
    K76.6Portal hypertension
    Q44.7Other congenital malformations of liver [Alagille syndrome]
    T86.41Liver transplant rejection
    K74.00Hepatic fibrosis
    1–10 of 13
    1/2
    Covered CPT Codes, Not Covered, Experimental, Presumptive (placeholder)mixed
    No codes listed
    Codes referencedmixed
    No CPT/HCPCS/ICD codes listed in this document excerpt.
    Covered/mentioned procedures (placeholder)mixed
    No codes listed
    Covered CPT Codes (placeholder)CPT
    No codes listed
    No codes listed in this document excerpt (placeholder)mixed
    No codes listed
    Imaging and elastography methods discussed (no billing codes listed)mixed
    No codes listed
    Serum biomarkers and miRNAs discussed (no billing codes listed)mixed
    No codes listed
    Referenced guideline and evidence sources (no billing codes)mixed
    No codes listed
    References do not list billing or procedure codesmixed
    No codes listed
    inv-52: Maximum medically necessary frequency
    Maximum frequency≤ 2 times per year for transient elastography, FibroTest-ActiTest/HCV‑FibroSure, magnetic resonance elastography, and ELF test
    Applies toTE (FibroScan), FibroTest/FibroSure, MRE, ELF
    RationalePolicy states performance >2/year is considered not medically necessary and may be denied
    inv-53: Minimum interval after liver biopsy or other fibrosis test
    Minimum interval after biopsy or other fibrosis test≥ 6 months before repeating a listed noninvasive fibrosis test
    IncludesTransient elastography, FibroTest/FibroSure, MRE, ELF
    ConsequenceTesting within 6 months may be considered not medically necessary and denied
    inv-54: FibroTest/FibroSure cutoffs referenced
    FibroTest categoriesFibroTest <0.32 = minimal fibrosis; 0.32–0.58 = moderate fibrosis; >0.58 = severe fibrosis (per Ngo et al and cohort analyses)
    Prognostic performanceFibroTest mean standardized AUROC ~0.84 across etiologies (Halfon et al meta-analysis)
    HepaScore exampleHepaScore ≥0.5 associated with significant fibrosis in original study
    inv-55: Test cutoffs and thresholds (APRI, FIB-4, TE)
    Key test cutoffsAPRI >2 indicates cirrhosis (WHO); FIB‑4 >3.25 indicative of cirrhosis per HCV guidance; TE >12.5 kPa consistent with cirrhosis
    ELF associationELF index >10.633 associated with cirrhosis (high AUC vs MRE)
    Context noteSpecific cutoffs vary by etiology, study, and test; document clinical context and numeric scores
    inv-56: FibroScan cutoffs reported
    Reported FibroScan cutoffsExamples: 7.3 kPa (F≥2), 9.8 kPa (F≥3), 17.3–17.6 kPa (F4/cirrhosis); cirrhosis cutoff 17.6 kPa yielded PPV/NPV ~90% in one study
    Higher complication thresholdsLS cutoffs reported for complications: 27.5, 37.5, 49.1, 53.7, 62.7 kPa for various outcomes in Foucher et al
    NotesCutoffs differ across studies; report median kPa and number of valid measurements when submitting results
    inv-57: ELF cutoffs reported
    ELF cirrhosis cutoffELF >10.633 associated with cirrhosis (AUC 0.986 vs MRE) — high specificity
    ELF advanced fibrosis cutoffsELF cutoffs in NAFLD cohorts: 9.34 (sensitivity ~90%) and 10.83 (specificity ~90%) reported; cutoff 10 associated with high specificity for advanced fibrosis
    Combination useSequential use of FIB‑4 and ELF improves sensitivity (example: FIB‑4 cutoff 2.67 then ELF 9.34)
    inv-58: Common LSM thresholds for fibrosis staging
    Common LSM rangesSignificant fibrosis (≥F2): ~7.0–8.6 kPa; Cirrhosis (F4): ~11.1–15.08 kPa across pooled studies
    Variation factorsLSM thresholds vary by ALT, BMI, steatosis and study methodology — tailored cutoffs may be needed
    Pooled cutoffs exampleMeta-analysis pooled LSM for F2 ~7.71 kPa and for F4 ~15.08 kPa (Stebbing et al)
    inv-59: Liver stiffness cut-offs examples
    Pediatric examplesTE optimal cut-off for pediatric F3‑F4 reported 8.6 kPa (Lee et al); pediatric pooled sensitivity 90% and specificity 79% (US elastography meta-analysis)
    CSPH cutpoint exampleTE cut‑off 21.6 kPa best predicted clinically significant portal hypertension with PPV 93% in Kumar et al
    ACR/graft examplesPost‑transplant studies report various cutoffs: >7.9–8.5 kPa suggests graft damage/ACR; <4.2–5.3 kPa may exclude ACR in some studies
    inv-60: Reported LSM cutoffs and thresholds (PSC)
    PSC LSM cutoffsPSC cohort reported cutoffs: ≥F1 7.4 kPa; ≥F2 8.6 kPa; ≥F3 9.6 kPa; F4 14.4 kPa (VCTE) — alternative cirrhosis cutoff ~13.7 kPa in one study
    Predictive valueLSM showed adjusted diagnostic accuracy 0.83 for severe fibrosis and 0.88 for cirrhosis in PSC cohorts
    Prognostic useBaseline LSM and LSM progression were independently linked to outcomes in PSC
    inv-61: MRE liver stiffness for ascites
    MRE ascites cutoffMRE-derived liver stiffness > 6.0 kPa associated with presence of ascites (optimal cutoff; AUROC 0.87)
    Clinical implicationLS >6.0 kPa was an independent risk factor for presence of ascites and higher cumulative incidence
    ComparisonMRE had higher diagnostic accuracy for ascites than serum fibrosis markers in Abe et al
    inv-62: liver cT1 prognostic cutpoint
    liver cT1 prognostic cutpoint> 825 ms associated with clinical outcomes (Jayaswal et al) — predicts combined clinical endpoint
    Comparative prognosticIn analysis accounting for unreliability, cT1 >825 ms predicted outcomes where TE >8 kPa did not retain significance
    ContextcT1 is an mpMRI metric used alongside TE and serum markers for prognostication in compensated chronic liver disease
    inv-63: Transient elastography fibrosis thresholds (UpToDate referenced)
    UpToDate referenced TE thresholds>7 kPa suggests significant fibrosis; >11–14 kPa suggests cirrhosis (UpToDate summary cited)
    Study-specific cutoffsMeta-analyses report F2 cutoffs ~7–8 kPa and cirrhosis cutoffs ~11–15 kPa depending on ALT and population
    Interpretation noteThresholds are approximate and should be interpreted with clinical/laboratory context (ALT, BMI, steatosis)
    inv-64: VCTE liver stiffness cutoffs (PSC)
    VCTE PSC cutoffs (repeated)PSC VCTE cutoffs: ≥F1 7.4 kPa; ≥F2 8.6 kPa; ≥F3 9.6 kPa; F4 14.4 kPa
    UtilityVCTE differentiates severe from non-severe fibrosis in PSC with good reproducibility
    Prognostic thresholdLSM prognostic threshold around 10.5 kPa reported in PSC prognostic analyses
    inv-65: Pediatric US elastography diagnostic performance
    Pediatric diagnostic performanceUS elastography in children: pooled sensitivity 90%, specificity 79%, AUROC 0.92 (Kim et al meta-analysis)
    TE in pediatricsTE optimal cutoffs vary by age; valid LSMs feasible in children >2 years; correlation with portal hypertension reported
    DocumentationRecommend documenting APRI and FibroScan and compare with histology when available in pediatric evaluations
    inv-66: LSM cut-offs for fibrosis stages (PSC cohort)
    PSC cohort LSM stagesLSM cutoffs for PSC cohort: ≥F1 7.4 kPa; ≥F2 8.6 kPa; ≥F3 9.6 kPa; F4 14.4 kPa
    Study exampleCorpechot et al and subsequent PSC studies reported high AUROCs for ≥F3 and F4 and prognostic value of LSM
    ReproducibilityHigh inter-operator reproducibility reported for LSM in PSC cohorts
    inv-67: Prognostic thresholds (LS and Anali score)
    Prognostic thresholdsLS prognostic threshold 10.5 kPa; Anali MRI score (without gadolinium) threshold = 2 — combination stratifies PSC risk
    Risk stratificationCombination of Anali ≥2 and/or LSM ≥10.5 kPa separates low/medium/high risk with 5‑year adverse outcome rates 8%, 16%, 38% respectively
    Clinical useCombine MRI score and LSM for improved prognostic classification in PSC cohorts
    inv-68: TE prognostic association (systematic review)
    TE prognostic associationTE >11.1 kPa associated with survival and liver-related complications in systematic review and pooled analyses
    Evidence breadthMultiple prognostic studies and systematic reviews support association between higher LSM and worse outcomes, though thresholds vary
    InterpretationPrognostic thresholds are study-dependent; report numeric LSM and clinical context
    inv-69: TE thresholds in post-transplant ACR studies
    Post‑transplant ACR TE thresholdsReported study cutoffs: >7.9 kPa suggests graft damage; >8.5 kPa for moderate-to-severe ACR; <5.3 kPa or <4.2 kPa may exclude graft damage/ACR in some studies
    Evidence limitationsData derive from small prospective studies and systematic reviews; TE cannot yet replace biopsy for ACR diagnosis
    RecommendationFurther studies required to validate cutoffs and distinguish ACR from other graft pathology

    Provider Actions — Documentation, Authorization, and Denial Risks

    Billing Rule

    Ensure claims use the listed CPT/ICD codes and document covered indication

    Claims for the CPT codes listed for transient elastography, FibroTest/FibroSure, magnetic resonance elastography, and ELF must be submitted with the matching ICD-10 diagnosis codes and supported by documentation showing the covered indication.

    • Examples of covered CPT codes: 76981, 91200 (transient elastography); 81596, 0003M (FibroTest/FibroSure); 76391 (MRE); 81517 (ELF).
    • Examples of covered ICD-10 codes when selection criteria are met: E83.110 (hereditary hemochromatosis), K75.81 (NASH), K76.0 (fatty liver), K83.01 (primary sclerosing cholangitis), B18.2 (chronic hepatitis C).
    Prior Authorization

    No prior authorization rules specified in excerpt

    This policy excerpt does not specify any prior authorization rules or list CPT codes that require prior authorization; check plan-specific Clinical Policy Bulletin for PA requirements.

    Prior Authorization

    Prior authorization overview — no PA mandates stated here

    The document provides no explicit prior authorization mandates in this excerpt; clinical performance characteristics (e.g., ELF vs MRE) are described but no PA criteria are given.

    Prior Authorization

    Consider documented indication when evaluating PA for noninvasive fibrosis tests

    Prior authorization considerations should account for documented clinical indication and the tests' greater accuracy for advanced fibrosis/cirrhosis versus earlier stages.

    • Tests like FibroScan and ELF are presented as diagnostic aids for cirrhosis and perform better for advanced fibrosis than for mild disease.
    • Document clinical rationale showing why noninvasive testing is indicated for the member’s condition.
    Documentation Required

    Document indication and interpretation factors for transient elastography (TE)

    When performing transient elastography (TE), document the clinical indication and factors that may affect interpretation (e.g., ALT, BMI, steatosis); TE is rapid, outpatient, and reproducible but has known limitations.

    • Record indication (e.g., chronic hepatitis C, PSC) and any confounders (ALT, BMI, presence of ascites) in the medical record.
    • Note that TE provides immediate results and median liver stiffness in kPa from multiple readings.
    Prior Authorization

    No explicit PA requirements in this excerpt — follow plan rules

    No prior authorization requirements are specified in this document excerpt; providers should follow plan-specific rules and the Clinical Policy Bulletin for any PA needs.

    Prior Authorization

    Prior authorization not specified in this section

    This section contains no specified prior authorization requirements; clinical validation studies are summarized but PA rules are not stated here.

    Note

    Regulatory and guideline context may affect PA decisions

    AACE guidance notes newer imaging techniques (e.g., LiverMultiScan, Velacur) have FDA approval for use in chronic liver disease but are largely used in research and require further assessment before routine diagnostic algorithm inclusion.

    • Consider guideline/regulatory context when requesting advanced imaging; document research vs clinical use as applicable.
    Prior Authorization

    No PA details provided in this excerpt — consult Clinical Policy Bulletin

    No explicit prior authorization codes or requirements are listed in the provided text; providers should consult the Clinical Policy Bulletin for plan-specific PA instructions.

    Prior Authorization

    Prior authorization not specified for listed modalities in this excerpt

    The extract does not state explicit prior authorization requirements for TE, MRI risk scoring, AI models, or serum biomarker testing; PA requirements, if any, depend on plan provisions.

    Note

    References cited — do not specify PA rules in this excerpt

    The reference list and cited guidelines are provided for context but do not themselves specify prior authorization requirements in this excerpt.

    • References include systematic reviews, technology assessments, and guidance relevant to noninvasive fibrosis testing.
    Prior Authorization

    Follow the Clinical Policy Bulletin and plan provisions for PA

    Refer to the Clinical Policy Bulletin and specific plan provisions for any prior authorization requirements for noninvasive hepatic fibrosis tests; this policy excerpt does not define PA procedures.

    Note

    No action stated

    No provider action is described in this placeholder block within the excerpt.

    Step Therapy

    Step therapy not specified — no mandated sequencing

    No step therapy sequencing requirements are specified in this excerpt; the literature discusses using noninvasive tests to triage or reduce biopsies but does not mandate a sequence.

    Step Therapy

    No step therapy requirements specified here

    No step therapy requirements are described in the provided text.

    Step Therapy

    Consider sequential testing (serum indices then ELF/LSM) before invasive testing

    Sequential or combined use of serum indices (e.g., FIB-4) followed by ELF or liver stiffness measurement can increase sensitivity/specificity and may be considered before invasive testing.

    • Sequential approach example: FIB-4 screening followed by ELF or FibroScan for confirmation increases diagnostic performance.
    • Document rationale and results when using sequential testing to avoid biopsy.
    Step Therapy

    Use TE plus serum markers before biopsy when clinically appropriate

    Combination of transient elastography with serum fibrosis markers increases diagnostic accuracy and may avoid biopsy for initial assessment in many chronic hepatitis C patients; document rationale when biopsy is deferred.

    • Combine TE with serum markers (e.g., FIB-4, APRI, ELF) to improve diagnostic accuracy.
    • If biopsy is not performed, record concordant noninvasive results and clinical decision justification.
    Note

    No action stated

    No provider action is described in this placeholder within the excerpt.

    Documentation Required

    Document combined serum + elastography testing strategy and results

    Combined use of serum tests and elastography increases diagnostic accuracy; providers should document the testing strategy (screening vs confirmatory) when using combined approaches.

    • Document which serum test(s) and elastography method were used, the numeric results, and how concordant/discordant results influenced management.
    Note

    VCTE/FibroScan commonly used and well-studied — document limitations

    Ultrasound-based transient elastography (VCTE/FibroScan) is the most-studied radiologic method for staging hepatic fibrosis and is commonly used as a first-line noninvasive test.

    • Recognize VCTE provides median LSM in kPa and is rapid with immediate results.
    • Be aware of limitations (obesity, ascites, high ALT) that can affect reliability.
    Step Therapy

    No step therapy requirements described

    No step therapy requirements are described in the referenced chunks.

    Step Therapy

    No step therapy requirements described

    No step therapy requirements are described in these chunks.

    Step Therapy

    No step therapy requirements in references listed

    References included in this section do not specify step therapy sequencing or mandates.

    Note

    No action stated

    No provider action is specified in this placeholder.

    Billing Rule

    Code the procedure and document the covered clinical indication

    Use the policy’s listed CPT and ICD-10 codes that correspond to the test and indication, and document the clinical indication consistent with covered ICD-10 codes when submitting claims.

    • Submit the CPT code that corresponds to the performed test (e.g., 76981, 91200, 81596, 76391, 81517) and an ICD-10 diagnosis code that matches the covered indication.
    • Ensure documentation in the chart supports the selected diagnosis code and medical necessity.
    Documentation Required

    Document test type and numeric score

    When noninvasive test results (e.g., FibroTest/FibroSure) are used clinically, document the test type and the numeric score or index value in the medical record.

    • Record score thresholds when relevant (e.g., FibroTest <0.32 minimal, 0.32–0.58 moderate, >0.58 severe).
    • Include date of test and correlation with any contemporaneous biopsy if performed.
    Documentation Required

    Document clinical evaluation including NITs and routine labs

    Clinical assessment should document noninvasive test results (FIB-4, APRI, transient elastography, proprietary serologic tests) and routine laboratory data (ALT, AST, albumin, bilirubin, INR, CBC with platelets) to establish presence or absence of cirrhosis.

    • Document how noninvasive results and routine labs support the clinical determination of cirrhosis.
    • Include imaging or physical findings (e.g., liver nodularity, splenomegaly) when present.
    Documentation Required

    Report median kPa and number of valid TE measurements

    When reporting liver stiffness by transient elastography, include the median kPa value and the number of valid measurements; document any comparators or cutoffs used to interpret results.

    • Record median LSM (kPa), number of valid readings, and the probe type (e.g., M or XL) if applicable.
    • Note the cutoffs applied (study or guideline-based) used to categorize fibrosis stage.
    Documentation Required

    Document APRI and FibroScan results in pediatric assessments

    In pediatric evaluations, document APRI score and FibroScan measurements when available and compare with histology if biopsy is performed.

    • Record age and any technical limitations (e.g., children <2 years have higher invalid scan rates).
    • Compare APRI and FibroScan results with biopsy histology if obtained.
    Documentation Required

    Document TE measurements and clinical context

    When using liver elastography, document the liver stiffness measurements and relate them to the clinical context; include any proposed cut-offs referenced from studies if used in decision-making.

    • Relate LSM to relevant prognostic thresholds when applicable (e.g., TE >11.1 kPa associated with complications; PSC thresholds vary).
    • Document any factors that could falsely elevate LSM (acute inflammation, high bilirubin).
    Documentation Required

    Correlate NITs with clinical context and document management implications

    Correlate noninvasive test results with clinical findings, labs, and imaging when making management decisions; document how concordant or discordant results influenced care.

    • If biopsy is deferred based on concordant noninvasive results, document the justification and follow-up plan.
    • Record any additional tests ordered to resolve discordant findings.
    Documentation Required

    Document study/validation details when using mpMRI/MRE metrics

    When imaging and biomarker studies are reported in research or validation settings, document study design elements including timing between imaging and biopsy and reported thresholds used for analysis.

    • Record interval between imaging and biopsy (ideally within 1 week) when used for validation.
    • Document reported cutoffs (e.g., mpMRI index cutoff 6) and cohort size if relevant to interpretation.
    Documentation Required

    Document imaging–biopsy interval when used for validation or diagnostic comparison

    When reporting elastography results in studies, note the time interval between imaging and biopsy (contemporaneous when possible) as this may affect diagnostic accuracy and interpretation.

    • Aim for contemporaneous imaging and biopsy within 1 week if feasible; if longer intervals were used, document the interval and rationale.
    Documentation Required

    Document LSM, Anali score thresholds and source study details when applied clinically

    Document reported liver stiffness measurement (LSM) thresholds, MRI Anali score threshold, and cohort sizes when these values inform clinical decisions (examples: LSM prognostic threshold 10.5 kPa; Anali score threshold 2).

    • Record thresholds used to stratify risk (e.g., PSC LSM cutoffs: ≥F1 7.4 kPa; ≥F2 8.6 kPa; ≥F3 9.6 kPa; F4 14.4 kPa).
    • Document cohort size or source study when applying study-derived thresholds to patient care.
    Note

    Evidence and guidance sources listed for reference

    Evidence syntheses, systematic reviews, and guidelines cited in the policy are available as reference but do not themselves specify provider documentation requirements beyond those noted elsewhere in the policy excerpt.

    Documentation Required

    Consult Clinical Policy Bulletin for documentation and plan provisions

    Refer to the Clinical Policy Bulletin for detailed documentation requirements and plan-specific provisions; this policy excerpt advises providers to follow those notes.

    Denial Risk

    Avoid overfrequency — >2/year may be denied

    Performing transient elastography, FibroTest/FibroSure, magnetic resonance elastography, or the ELF test more than twice per year is considered not medically necessary and may be denied.

    • Maximum medically necessary frequency for these tests: ≤ 2 times per year.
    Denial Risk

    Do not repeat listed NITs within 6 months of biopsy or another fibrosis test — risk of denial

    Performing these noninvasive tests within 6 months following a liver biopsy (or another listed fibrosis test) is considered not medically necessary and may be denied.

    • Do not repeat listed noninvasive fibrosis tests within 6 months of a liver biopsy or another specified fibrosis test unless clinically justified and documented.
    Note

    No action stated

    No provider action is described in this placeholder block within the excerpt.

    Note
    Denial Risk

    Do not use TE to diagnose cirrhosis during acute liver injury — risk of false positives/denial

    This policy warns that transient elastography is unreliable for detecting cirrhosis during acute liver injury; TE may yield pathologically high values and could be denied if used to justify interventions based on presumed chronic cirrhosis.

    • Avoid relying on TE to diagnose pre-existing cirrhosis during an episode of acute liver damage; document alternative assessments or follow-up when acute injury is present.
    Denial Risk

    TE unreliable in acute liver damage — document timing and interpret with caution

    Transient elastography frequently yields pathologically high values in acute liver damage and is unsuitable for detecting chronic fibrosis/cirrhosis in that context; document if TE is performed during acute injury and interpret cautiously.

    • If TE is performed during acute hepatic injury, document the timing and note that elevated LSM may reflect acute inflammation rather than chronic fibrosis.
    Note

    No action stated

    No provider action is described in this placeholder block within the excerpt.

    Note

    No action stated

    No provider action is described in this placeholder block within the excerpt.

    Note

    No coverage statements in this placeholder

    No explicit coverage statements are provided in this placeholder portion of the excerpt.

    Note
    Denial Risk

    Limited evidence for some uses may prompt additional review or denial risk

    Limited or evolving evidence for some modalities may affect claim adjudication; providers should document clinical rationale and cite relevant evidence when appropriate.

    • Limited evidence for certain indications (e.g., TE for graft rejection) may lead to additional review or request for documentation.
    Note

    References do not specify denials; follow policy criteria

    References cited in the policy excerpt do not themselves specify denial triggers; denial risk statements in the policy are based on frequency, duplication, and context (e.g., acute injury).

    Note

    Follow the current Clinical Policy Bulletin — policies may change

    Policies are subject to update; failure to follow the current Clinical Policy Bulletin may affect coverage determinations — verify current policy version and plan provisions.

    • Last review date: 02/20/2024; next review scheduled 07/25/2024.
    • Ensure claims and documentation reflect the current Clinical Policy Bulletin requirements.

    Background — Clinical Context and Evidence Summary

    The background summarizes the clinical context: hepatic fibrosis is progressive scarring from chronic liver injury of diverse etiologies. Liver biopsy remains the diagnostic gold standard, while noninvasive serum and imaging tests have been developed to estimate fibrosis and may reduce biopsy use in selected patients; however, evidence is limited and many studies are cross‑sectional with few long‑term outcome data.

    Definitions — Tests, Metrics, and Terms

    inv-120: Hepatic fibrosis definition
    DefinitionHepatic fibrosis: excessive accumulation of fibrotic connective tissue from prolonged inflammation and progressive scarring of the liver; leads to increased stiffness and reduced blood flow
    EtiologiesIncludes alcoholic liver disease, chronic hepatitis B and C, NAFLD/NASH, hereditary hemochromatosis
    Clinical noteLiver biopsy is diagnostic gold standard but is invasive; noninvasive tests aim to estimate fibrosis and reduce biopsy risks
    inv-121: FibroTest/FibroSure definition
    Test descriptionFibroTest/FibroSure: serum biochemical panels using markers (alpha2‑macroglobulin, haptoglobin, GGT, total bilirubin, apolipoprotein A1, ALT) plus age and sex applied to an algorithm to estimate fibrosis and necroinflammatory activity
    VariantsMarketed as HCV‑FibroSure, ASH FibroSure, NASH FibroSure with additional markers for steatosis/NASH
    UseUsed to distinguish cirrhosis from non‑cirrhosis in chronic liver disease per policy
    inv-122: Significant fibrosis definition (METAVIR F2+)
    Significant fibrosis definitionOften defined as METAVIR stage F2 or greater (or modified Ishak score ≥3 in some studies)
    ImplicationMany noninvasive test performance metrics use F2+ as the threshold for 'significant fibrosis' in diagnostic studies
    NoteAccuracy for distinguishing early stages (F1–F2) is lower than for advanced fibrosis/cirrhosis
    inv-123: AUROC definition
    AUROC definitionArea under the receiver-operating characteristic curve — a measure of diagnostic test accuracy used throughout analyses
    InterpretationHigher AUROC indicates better discrimination; values reported across studies guide comparative performance
    ExamplesFibroTest mean AUROC ~0.84; ELF AUC up to 0.986 for cirrhosis in a cohort vs MRE
    inv-124: ELF definition
    ELF test componentsELF combines hyaluronic acid (HA), procollagen III N-terminal peptide (PIIINP), and TIMP‑1 to generate an index for fibrosis assessment
    ManufacturerELF test by Siemens Healthcare
    Clinical performanceELF shows high AUC for cirrhosis and may outperform some serum indices in select cohorts
    inv-125: APRI / FIB-4 definition
    APRI / FIB‑4 descriptionAPRI and FIB‑4 are serum-based indices calculated from routine labs (AST, platelet count, age) used to noninvasively assess fibrosis; specific cutoffs classify significant fibrosis or cirrhosis
    ExamplesWHO recommends APRI >2 for cirrhosis in resource‑limited settings; FIB‑4 >3.25 used to indicate cirrhosis per HCV guidance
    RoleOften used as initial screening tests or part of sequential algorithms with imaging/ELF
    inv-126: Transient elastography definition
    Transient elastography (TE) definitionUltrasound-based technique (e.g., FibroScan) measuring liver stiffness by shear wave velocity; outputs median stiffness in kPa from multiple readings
    Device componentsControl unit, low-frequency vibration emitter, ultrasound probe; median of ~5–10 readings used
    Clinical rangeIn cirrhotic patients, LSM ranges reported from ~12.5 to 75.5 kPa
    inv-127: ELF Test definition (redundant)
    ELF test (redundant)Blood-based algorithm combining HA, PIIINP, and TIMP‑1 yielding an ELF index for fibrosis estimation
    Clinical noteUsed for detection and prognosis of advanced fibrosis/cirrhosis in chronic liver disease cohorts
    CutoffsELF >10.633 linked to cirrhosis in cohort vs MRE
    inv-128: Transient elastography (FibroScan) key definition
    FibroScan (TE) key definitionVibration-controlled transient elastography (FibroScan) measures liver stiffness (LSM in kPa) via propagation speed of elastic shear waves; median reported
    OutputMedian kPa value from multiple valid measurements; number of valid measures should be reported
    UseUsed to estimate fibrosis stage and detect cirrhosis; thresholds vary by study and etiology
    inv-129: TE/FibroScan concise definition
    TE / FibroScan concise definitionBedside ultrasound-based elastography providing rapid, reproducible liver stiffness measurements (kPa) to assess hepatic fibrosis
    AdvantagesRapid outpatient test with immediate results and good reproducibility; failure rates ~2.7–5% (higher in obesity)
    LimitationsValues can be transiently elevated in acute liver injury, influenced by ALT, BMI, and steatosis
    inv-130: LSM cut-off definition
    LSM cut‑off conceptAn LSM cut‑off is a kPa threshold used to categorize likelihood of significant fibrosis (approx. 7–8 kPa) or cirrhosis (approx. 11–15 kPa); thresholds vary by study and patient factors
    Reporting guidanceReport median kPa and number of valid measurements and interpret in clinical context (ALT, BMI, etiology)
    Use cautionOverlap between stages and heterogeneity across studies limits a single universal cutoff
    inv-131: Clinically significant portal hypertension (CSPH) definition
    CSPH definition (clinically significant portal hypertension)Often defined by HVPG ≥10 mm Hg; associated with increased risk of decompensation and development of varices
    TE roleTE has been studied as a noninvasive proxy for CSPH with varying thresholds and reasonable correlation to HVPG (correlation ~0.75)
    Example cutoffTE cutoff 21.6 kPa reported to best predict CSPH with PPV 93% in a retrospective study
    inv-132: Esophageal varices detection by TE definition
    Esophageal varices detection by TETE used to predict presence/size of esophageal varices with pooled AUROC ~0.83; pooled sensitivity ~0.81 and specificity ~0.71 for large varices
    LimitationsLS cutoffs vary across studies and heterogeneity limits universal application; TE useful as screening adjunct rather than definitive diagnostic test
    Clinical implicationTE may reduce need for endoscopy in selected low‑risk patients when combined with other markers
    inv-133: LiverMultiScan / mpMRI definition
    LiverMultiScan / mpMRI definitionMultiparametric MRI approach (LiverMultiScan) quantifying liver composition (PDFF, T1/T2 mapping, cT1) to noninvasively assess steatosis, iron, and fibrosis
    ComponentsMay include PDFF, iron-corrected T1 (cT1), T1/T2 mapping and derived indices to aid diagnosis (e.g., NASH) and prognosis
    Evidence statusPromising but requires further multicenter validation before routine replacement of biopsy
    inv-134: VCTE/FibroScan definition
    VCTE / FibroScan definitionVibration-controlled transient elastography (VCTE/FibroScan) is an ultrasound-based elastography measuring liver stiffness (LSM in kPa) as a surrogate for fibrosis stage
    Output and useProduces median kPa from multiple valid measures; widely studied for staging fibrosis and detecting cirrhosis
    LimitationsAffected by obesity, ascites, acute inflammation; failure rates and cutoffs vary by population
    inv-135: mpMRI / LiverMultiScan definition (redundant)
    mpMRI / LiverMultiScan (redundant)Multiparametric MRI combining measures (MRS, MRE, T1 mapping, PDFF, cT1) to quantify liver fat and fibroinflammatory changes and generate indices for NASH/fibrosis
    Clinical roleMay aid in diagnosing NASH and monitoring therapy; further validation needed
    Research noteRADIcAL1 and other trials are evaluating clinical-utility and cost-effectiveness
    inv-136: Magnetic resonance elastography (MRE) definition
    MRE definitionMagnetic resonance elastography (MRE) uses a vibration source and phase-contrast MRI to image propagating mechanical waves and compute quantitative tissue stiffness (LS) in the liver
    AdvantagesAssesses 3D wave propagation and has strong correlation with histologic fibrosis stage and high diagnostic accuracy in many studies
    Clinical usesUsed for fibrosis staging, NASH assessment, and predicting complications (eg, ascites) with specific cutoffs reported
    inv-137: LS cutoff for ascites prediction (MRE)
    MRE LS cutoff for ascites predictionLS > 6.0 kPa identified as optimal cutoff for presence of ascites (AUROC 0.87) in Abe et al
    Clinical implicationMRE-derived LS >6.0 kPa associated with higher cumulative incidence of ascites
    ComparisonMRE outperformed serum fibrosis markers for predicting ascites in the cited study
    inv-138: ARFI definition
    ARFI definitionAcoustic Radiation Force Impulse (ARFI): ultrasound technique using short high-intensity acoustic pulses to measure shear wave velocity (m/s) and tissue elasticity
    Clinical noteEvidence favourable in some settings but lacks robust guideline-level validation compared with biopsy in many indications
    Policy stanceARFI considered investigational for distinguishing cirrhosis from non‑cirrhosis per policy
    inv-139: LSM (VCTE) definition
    LSM (VCTE) definitionLiver stiffness measurement (LSM) by VCTE: numeric kPa value correlated with fibrosis stage; used to estimate fibrosis and prognosticate in chronic liver disease
    PSC examplePSC-specific cutoffs reported (≥F1 7.4, ≥F2 8.6, ≥F3 9.6, F4 14.4 kPa)
    ReportingDocument median kPa, number of valid measures, and clinical context when using LSM
    inv-140: LSM (Liver Stiffness Measurement) definition
    LSM (Liver Stiffness Measurement)Numeric liver stiffness measured by transient elastography (kPa) used to estimate fibrosis stage and predict outcomes; thresholds vary by study
    MeasurementMedian of multiple valid readings (typically 5–10) reported in kPa
    InterpretationInterpret in context of ALT, BMI, steatosis, and etiology; overlapping values across fibrosis stages limit binary classification without context
    inv-141: Anali score (without gadolinium) definition
    Anali score (without gadolinium) definitionMRI-derived score: (1 × biliary dilatation) + (2 × dysmorphy) + (1 × portal hypertension); threshold of 2 used for prognostic stratification in PSC
    UseCombined with LSM improves prognostic stratification in PSC cohorts
    ThresholdAnali >=2 considered prognostic cutoff in cited study
    inv-142: ELF test (definition redundant)
    ELF test (redundant)ELF is a serum biomarker panel combining HA, PIIINP, and TIMP‑1 generating an ELF index for fibrosis assessment and prognosis
    Clinical noteELF demonstrated high specificity for advanced fibrosis at certain cutoffs and high AUC for cirrhosis in a comparative cohort vs MRE
    RoleMay be used alone or sequentially with FIB‑4/TE to improve diagnostic accuracy
    inv-143: FibroScan definition (reference support)
    FibroScan definition (reference support)FibroScan (VCTE) is a bedside ultrasound elastography device that measures liver stiffness (kPa) by propagation speed of shear waves; median value used for interpretation
    EvidenceExtensively cited in literature for noninvasive staging of fibrosis and cirrhosis
    LimitationsAffected by acute inflammation and technical failures in obesity/ascites
    inv-144: MRE definition (reference support)
    MRE definition (reference support)MRE is an MR-based imaging technique that generates mechanical waves and quantifies liver stiffness (LS) in kPa, correlating strongly with histologic fibrosis stage
    Clinical utilityUsed for fibrosis staging, superior accuracy vs TE in some studies for NAFLD/NASH
    Research noteReferenced in multiple systematic reviews and comparative studies
    inv-145: Serum fibrosis markers definition
    Serum fibrosis markersBlood-based biomarker panels (e.g., FibroTest, ELF, HepaScore) and individual markers (HA, PIIINP, TIMP‑1, CK‑18, miRNAs) proposed as noninvasive predictors of fibrosis severity
    PerformancePerformance varies by etiology and stage; some markers show good AUROC for advanced fibrosis but limited accuracy for early stages
    Policy noteSome serum markers are considered investigational for specific indications per policy (see experimental list)
    inv-146: Quantitative MRI / LiverMultiScan definition
    Quantitative MRI / LiverMultiScan definitionQuantitative multiparametric MRI (LiverMultiScan) provides MRI-based biomarkers (PDFF, cT1, T1/T2 maps) to characterize liver tissue composition and generate indices for NASH/fibrosis assessment
    StatusPromising diagnostic tool with prospective validation studies but insufficient evidence for routine replacement of biopsy
    Use caseMay aid in diagnosis and monitoring; ongoing trials (eg, RADIcAL1) evaluate clinical‑utility and cost-effectiveness
    inv-147: FibroScan definition (reference support, duplicate)
    FibroScan definition (support duplicate)FibroScan (transient elastography) — ultrasound-based noninvasive method measuring liver stiffness as a surrogate for fibrosis stage; median kPa value from multiple readings
    Regulatory noteDevice has FDA 510(k) summaries referenced in literature
    Operational noteReport median kPa and number of valid measurements; consider technical failure rates in obese patients

    Revision History

    2004-08-13effective

    Policy became effective on 2004-08-13.

    2024-02-20last_reviewLatest

    Policy last reviewed on 2024-02-20.

    2024-07-25next_review_scheduled

    Next scheduled policy review on 2024-07-25.